Differences in clinical studies and pharmacovigilance of biological drugs in Latin America

Biosimilars/Research | Posted 14/01/2022 post-comment0 Post your comment

Clinical studies are trials conducted in humans to test the efficacy of new drugs, devices, and other forms of treatment, as well as those already approved. On the other hand, preclinical or non-clinical studies are in vitro or in vivo studies, carried out on animals, which are necessary to evaluate the toxicity of the product and prove drug safety.

Clinical Trials 2 V13K29

Clinical and non-clinical information can be classified into four types of studies [1]:

  1. Preclinical: include in vitro and animal population experiments, which seek to obtain information regarding efficacy, toxicity, and pharmacokinetics; and for pharmaceutical companies to decide whether to continue with clinical studies.
  2. Phase I Clinical Studies: studies with a small group of people (20 to 80), to determine the safety, tolerability, and pharmacokinetic and pharmacodynamic parameters of the drug. Dosage ranges are also included to find the appropriate ones. They are usually conducted with healthy volunteers, but there are exceptional cases, such as in oncology and Human Immunodeficiency Virus (HIV) trials.
  3. Phase II Clinical Studies: work is done with larger groups (20 to 300 people). They can be divided into IIA (dosage requirements, i.e. how much should be administered) and IIB (efficacy).
  4. Phase III Clinical Studies: multicentre studies with a large number of patients (300 to 3,000, a larger number may be required) to assess the effectiveness of the drug in comparison with the standard of care.

Table 1 presents the clinical and non-clinical information required by current regulations for the health registration of biological and/or biotechnological products in each of the country’s studies in Central America and the Caribbean, including Brazil and Chile.

Table 1: Clinical and non-clinical information required for registration of biologics and biotechnology products in the nine Latin American countries
Country Clinical and non-clinical information
Brazil - Non-clinical studies
- Clinical studies
Chile - Preclinical studies
- Phase I, II, and III clinical studies
Costa Rica - Conclusive report of preclinical studies
- Conclusive report from phase I, II and III clinical studies
Cuba - Written summary of module 2
- Non-clinical information (module 4) and clinical information (module 5)
El Salvador - Pharmacological informatio
- Conclusive report of preclinical studies
- Conclusive report of clinical studies
Guatemala -  Phase I, II, and III clinical studies
Honduras

- Preclinical information

- Phase III clinical studies

Panamá -  Preclinical and clinical studies demonstrating safety, efficacy and quality of the product
Dominican Republic - Non-clinical studies
- Phase I, II, and III clinical studies

 

Some of the regulations evaluated require information from all types of studies, both clinical and preclinical, as is the case in Costa Rica, El Salvador, Panama, the Dominican Republic, Brazil, and Chile. In Guatemala, by contrast, preclinical studies are not requested. And in the case of Honduras, with respect to clinical information, only phase III information is of interest, possibly assuming that it has already gone through the two previous stages.

Pharmacovigilance refers to the set of activities related to the detection, evaluation, understanding, and prevention of adverse effects or any other drug-related issues. At this stage in which biological and biotechnological products are used with increasing frequency, these actions are necessary to ensure their safety and effectiveness, as some rare adverse effects are only detected after the product is marketed. For this reason, health registration calls for a risk management and post-marketing pharmacovigilance plan. Of all the countries studied, Honduras is the only country that does not request it. In Cuba and Chile, this process is also explained in detail, indicating how to complete the report and the information it should contain.

In the search for divergences in the clinical and non-clinical information requested, as well as in pharmacovigilance programmes in the nine Latin American countries, significant differences were found throughout the study.

Editor’s comment
Readers interested to learn more about pharmacovigilance of biologicals/biosimilars are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

Pharmacovigilance, traceability and building trust in biosimilar medicine

Roundtable on biosimilars: pharmacovigilance, traceability, immunogenicity, 15 November 2016, Madrid, Spain

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper in Spanish and/or English to GaBI Journal – an independent, peer reviewed academic journal – please submit your manuscript here.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
2.2 – CiteScoreTracker 2021 (Last updated on 5 January 2022)

Submit a manuscript to GaBI Journal

Related articles
Differences in immunogenicity, pharmacovigilance and legal documents in biological products in Latin America

Regulations of the registration of biosimilars in Latin America

Definition of biological terms in Latin America

Regulation of the registration of biological drugs in Latin America

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Diferencias en estudios clínicos y farmacovigilancia de medicamentos biológicos en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Diferencias en estudios clínicos y farmacovigilancia de medicamentos biológicos en América Latina

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

Reference
1. Ramirez-Telles M, Mora-Roman Jose J, Fallas-Cartin M. Registro sanitario de medicamentos biológicos y biotecnológicos en América Latina. Ars Pharm. 2021;62(2):131-43.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Successful trials for Sandoz and Lannett biosimilars
Clinical Trials 2 V13K29
Biosimilars/Research Posted 30/09/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010